SCHEMBL2660107

SCHEMBL2660107

COc1cccc(-c2cccc3c(N)c4c(nc23)CN(C2=CC=C2)C4=O)c1C#N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ HPGD P15428 3/20 0.35
▸ PRMT5 O14744 1/20 0.34
▸ WDR77 Q9BQA1 1/20 0.34
▸ MEN1 O00255 4/20 0.33
▸ KMT2A Q03164 4/20 0.33
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ HTT P42858 1/20 0.32
▸ BLM P54132 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ HSP90AA1 P07900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655753 0.89 UGCG (0.39) ALDH1A1HPGDMEN1KMT2AMAPT
SCHEMBL2661383 0.89 CYP3A4 (0.34) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL2658032 0.87 UGCG (0.33) ALDH1A1MEN1KMT2AMAPTADORA2A
SCHEMBL2658318 0.84 GABRG2 (0.37) GABRG2GABRB3GABRA2UGCG
SCHEMBL2657086 0.84 UGCG (0.36) ALDH1A1MEN1KMT2AMAPTADORA2A
SCHEMBL2657233 0.84 GABRA1 (0.43) ALDH1A1MEN1KMT2AMAPTADORA2A
SCHEMBL2657791 0.84 GABRG2 (0.43) MEN1KMT2ATSHRADORA2AGABRG2
SCHEMBL2660596 0.84 HSP90AA1 (0.35) ALDH1A1MEN1KMT2AMAPTACHE
SCHEMBL2661564 0.83 DPP4 (0.33) —
SCHEMBL2660785 0.83 GABRG2 (0.43) TSHRGABRG2GABRB3GABRA2UGCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF ALDH1A1 442/4885KDM4E 2357/4885HPGD 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback